Geneva Partners LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 56.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,014 shares of the company’s stock after selling 5,215 shares during the period. Geneva Partners LLC’s holdings in Johnson & Johnson were worth $711,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at $26,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $38,000. Advocacy Wealth Management Services LLC boosted its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $49,000. Institutional investors and hedge funds own 68.78% of the company’s stock.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Down 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the prior year, the firm earned $2.48 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.
Analysts Set New Price Targets
A number of brokerages have issued reports on JNJ. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Morgan Stanley raised their price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Finally, Wells Fargo & Company raised their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.